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Linear scleroderma is a form of localized scleroderma characterized by sclerotic 
lesions distributed in a linear, band-like pattern. The “en coup de sabre” subtype 
of linear scleroderma is more often associated with systemic morbidity, including 
ocular, oral, and neurological abnormalities. Here, we report one patient with 
typical linear scleroderma “en coup de sabre” (LSCS). Initially, he presented with 
refractory partial seizures before the characteristic skins lesion on his head devel-
oped. This was a rare case with obvious brain parenchyma involvement. We did not 
prescribe medication but performed serial brain magnetic resonance imaging 
follow-up for the intraparenchymal lesion. The atrophic changes of the skin, face and 
brain remained the same, and his seizures had not worsened at the most recent 
follow-up. Parry-Romberg syndrome, a very similar condition, should be differenti-
ated from LSCS.
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1. Introduction
Scleroderma is a rare disease of unknown etiology, 
with skin involvement, that may be diffuse or 
localized. Linear scleroderma is a unique form of 
localized scleroderma that primarily affects the 
pediatric population, with 67% of patients diagnosed 
prior to 18 years of age.1
When linear scleroderma occurs on the head, it is 
referred to as linear scleroderma “en coup de sabre” 
(LSCS). Addison first coined the term in 1854, given 
the similarity of the scar resulting from a saber 
sword cut.2 Facial hemiatrophy may develop as a 
result of hypoplasia of the underlying bone and soft 
tissues. Here we present an 8-year-old boy who 
initially presented with refractory partial seizures 
before the characteristic skin lesion on the head 
developed. This was an extremely rare case with 
obvious brain parenchyma involvement.
2. Case Report
This patient was an 8-year-old boy who was born 
at term without perinatal asphyxia insult. The fam-
ily history was uneventful. Milestones were reached 
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at normal ages. His initial motor and mental devel-
opment was normal. At the age of 5, he started to 
experience seizures. The initial seizure pattern 
showed eye deviation to the left but no loss of con-
sciousness, and they resolved in 3 minutes. Seizures 
with lapses in consciousness and fumbling of hands 
had developed 2 years prior to admission. The sei-
zures were refractory to multiple antiepileptic 
agents (carbamazepine, phenobarbital, clobazam, 
and sodium valproate). Brain computerized to-
mography findings were initially normal.
There was a small wound scar over the patient’s 
right frontal scalp after head trauma at 4.5 years 
of age. The size of the scar enlarged gradually after 
seizure onset. The scar extended from the vertex 
scalp to the right side of the nose, covering the 
right frontoparietal scalp with atrophic changes, 
alopecia, and pigmentation (Figure 1). There was no 
history of exposure to drugs, radiation, tick bites, 
or chemical exposure.
Physical examination disclosed the characteris-
tic clinical findings involving the right frontal and 
parietal areas as mentioned above, and the scar 
did not extend below the forehead. There were no 
other morphea lesions on the patient’s body. His 
height, weight, and head size were all within nor-
mal range. Neurologic examination revealed left 
homonymous hemianopsia; all other cranial nerves 
were intact. Higher brain function was normal. The 
muscle strength and deep tendon reflexes in the 
bilateral limbs were symmetric and normal. Babinski’s 
reflex was negative. The patient’s total intelli-
gence quotient at age 7 was estimated to be 77 
using the Wechsler Intelligence Scale for Children 
(version III).
Serial follow-up with brain magnetic resonance 
imaging (MRI) from 6−8 years of age revealed pro-
gressive atrophy and prominent T2 signals in the sub-
cortical white matter of the right temporal−occipital 
lobes (Figure 2). Ictal video electroencephalogra-
phy revealed onset of seizure focus either from the 
right mid-posterior temporal region, or the right 
fronto-central region. Positron emission tomogra-
phy showed hypometabolism in the same area 
(Figure 3). Laboratory studies including complement 
component 3 and 4, antinuclear antibody, anti-
dsDNA, anti-centromere Ab and anti-Scl 70 were 
all within normal limits. Magnetic resonance spec-
troscopy excluded the possibility of tumor, but 
showed gliotic change.
The characteristic skin lesion suggested diagno-
sis of LSCS. We did not prescribe medication but 
performed serial MRI follow-up for the intraparen-
chymal lesion. The atrophic change of the skin on 
the face and brain remained the same at the most 
recent follow-up (Figure 2). The patient’s seizures 
did not worsen and were well controlled with a 
combination of oxcarbazepine, sodium valproate, 
and vigabatrin since 7.5 years of age. The patient 
was able to get fair academic achievement as a 
common elementary school student.
3. Discussion
Localized scleroderma can be divided into five 
main types: bullous morphea, plaque morphea, 
generalized morphea, deep morphea, and linear 
scleroderma.3 The annual incidence rate of local-
ized scleroderma has been estimated to be 27 new 
cases per million.4 Overall survival is similar to 
that of the general population. The pathogenesis 
of localized scleroderma is still poorly understood. 
Endothelial cell damage leading to increased fi-
broblast activity and ischemia—through luminal 
narrowing with subsequent modification of colla-
gen production—has been proposed as the patho-
genic mechanism, showing marked similarities to 
Figure 1 Pictures taken at age 7 revealed that the size of the head trauma-related scar enlarged gradually after 
onset of seizures. The scar extended from the vertex scalp to the right side of the nose, covering the right frontopa-
rietal scalp, with atrophic changes, alopecia and pigmentation.
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Figure 2 Serial follow-up of brain magnetic resonance imaging (MRI; T2W, axial and coronal view) of the patient. 
From left to right are MRI scans at age 7, 7.5, and 8.5. Progressive atrophy and prominent T2 signal in the subcortical 
white matter of right temporal−occipital lobes were initially noted. The atrophic change in the brain remained the 
same in the most recent follow-up (age 8.5). MR spectroscopy excluded the possibility of tumor, but showed gliotic 
change.
Figure 3 Fluorodeoxyglucose-positron emisson tomography study showed hypometabolism in the right temporal−
occipital area.
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systemic sclerosis.5,6 Borrelia burgdorferi7−9 or 
viral infection,10,11 genetic factors,12 and preced-
ing trauma13,14 may play roles in its development.
Linear scleroderma presents as band-like le-
sions with hardening of the skin and pigmentary 
changes. There is deep atrophy with involvement 
of muscle and bone. It most commonly develops in 
the first or second decade of life. The lower ex-
tremities are more commonly involved than face 
or scalp. Unlike most forms of localized sclero-
derma, which have a 3:1 female predominance, 
linear scleroderma has equal affect in males and 
females.4
“En coup de sabre” is a rare subset of linear 
scleroderma, with the active stage usually lasting 
2−5 years.15 Initially, it is characterized by ivory-
colored, sclerotic plaques with violaceous borders 
distributed in a band-like fashion on the frontopa-
rietal scalp and forehead, which rarely progress 
down to the face. Alopecia of the affected scalp is 
common, and so is the deformity of the skull. The 
diagnosis of LSCS is based on clinical pictures, re-
lying on the characteristic cutaneous and soft tis-
sue findings on the forehead and scalp.5,15,16 
Currently there are no definitive diagnostic labo-
ratory tests for linear scleroderma. An autoim-
mune etiology has been advocated. Antinuclear 
antibody with homogeneous and speckled patterns 
are positive in 37−50% of patients with linear 
scleroderma.4,5,15 Antibodies to single-stranded 
DNA, Scl-70, anti-centromere, Anti-Ro/La antibody, 
and U1RNP may be present and precede the devel-
opment of systemic disease.5
Unlike most localized sclerodermas, which are 
without extracutaneous involvement, the LSCS is 
more often associated with systemic morbidity, in-
cluding ocular, oral, and neurological abnormalities. 
However, obvious involvement in brain parenchyma 
is rare. The pathogenesis of atrophic change in the 
brain is unknown. It was suspected to be a muco-
cutaneous syndrome of vascular dysplasia, similar to 
the Sturge-Weber syndrome described Chung et al in 
1995.17 However, an early inflammatory stage was 
speculated and proved by recent neuropathology 
studies—involving cerebral blood vessels and re-
sulting late-stage changes of focal cerebral necro-
sis, neuron loss, ectatic vessels, and gliosis.18,19 
The origin and relationship between localized sclero-
derma and progressive focal atrophic change in 
the brain remain to be clarified.
Parry-Romberg syndrome (PRS), a very similar 
condition that should be differentiated with 
LSCS, has similar autoimmune serological, neuro-
logical, and intracranial manifestations.20 Some 
authors consider LSCS and PRS to be overlapping 
conditions.21 However, in PRS unlike linear sclero-
derma, the skin usually shows no induration, and 
the progressive hemifacial atrophy is more pro-
minent.21,22 The comparison of PRS and LSCS is 
shown in Table 1.4,5,12,15,16,20−22
Both LSCS and PRS have been reported in 
association with headache, focal seizures, mental 
deterioration, and oral/ophthalmological abnor-
malities.23 Neurologic complications are the most 
common systemic association with LSCS. Complex 
partial seizures have been reported most 
frequently,24,25 but the neurologic symptoms are 
rarely associated with detectable brain lesions. 
Neuroradiologic abnormalities including cerebral 
atrophy, white-matter lesions, intraparenchymal 
calcification, meningocortical alterations and skull 
atrophy have been desc ribed in the literature.19,26−29 
There is generally no correlation between the se-
verity of brain anomalies and the clinical picture.
Table 1 Comparison of Parry-Romberg syndrome (PRS) with linear scleroderma “en coup de sabre” (LSCS)
 PRS LSCS
Gender (female:male) 3:2 1:1
Induration of skin No Yes
Predilection More on the left side of face No
Location of initial lesion Cheek and nose Forehead and scalp
Behavior of invasion Usually does not cross the Usually does not extend
  midline; more extensive  below the forehead
  involvement of the lower face
Intracranial involvement  Yes Yes
Systemic involvement No Yes
Etiology Unknown etiology ANA(+): 35−50%
  Rheumatologic disease
   coexists with or precedes SLE 
Treatment No specific therapy Immunosuppressive
   treatments may be useful
ANA = antinuclear antibody; SLE = systemic lupus erythematosus.
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There is no effective treatment for LSCS so 
far. However, immunosuppressive agents such as 
D-penicillamine, cyclosporine, methylprednisolone, 
interferon, and methotrexate might be considered 
to stop the progressive atrophy of the brain.30−32
In our case, the partial seizures occurred be-
fore the appearance of LSCS and development of 
brain atrophy. We therefore recommend serial fol-
low-up with brain MRI when treating patients with 
focal scleroderma involving the scalp or the face.
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